BridgeBio Pharma, Inc. (BBIO) Income Statement
BBIO 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBBIO revenue and net income
Where BBIO's revenue goes
2025Each bar shows an amount and its share of revenue. BBIO kept −145.3% of revenue as net income.
BBIO profit margins
BBIO growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +126.3% | +86.3% | +127.4% | — |
| Gross profit | +117.3% | +85.5% | +124.8% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BBIO quarterly EPS vs estimates
BridgeBio Pharma beat the analyst EPS estimate in 2 of the last 8 quarters. Next report: November 4, 2026 (estimate $-0.63).
BBIO income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $502.1M | $221.9M | $9.3M | $77.6M | $69.7M | $8.2M | $40.6M | $0 | $0 |
| Cost of revenue | $28.3M | $3.9M | $2.4M | $3.4M | $3.1M | $3.1M | $2.5M | — | $260,000 |
| Gross profit | $473.8M | $218.0M | $6.9M | $74.2M | $66.6M | $8.2M | $38.1M | — | −$260,000 |
| Research & development | $477.5M | $506.5M | $455.7M | $399.5M | $451.0M | $337.0M | $209.9M | $140.1M | $30.6M |
| Sales, general & admin | $531.2M | $272.4M | $150.6M | $143.2M | $192.2M | $145.7M | $94.4M | $43.6M | $13.3M |
| Total operating expenses | $1.04B | $811.0M | $614.2M | $586.4M | $643.2M | $482.7M | $304.3M | $183.7M | $43.9M |
| Operating income | −$569.1M | −$593.0M | −$607.4M | −$512.2M | −$576.6M | −$474.5M | −$266.2M | −$183.7M | −$43.9M |
| Interest income | $19.9M | $17.2M | $18.0M | $7.5M | $1.1M | $4.0M | $8.9M | $2.0M | $39,000 |
| Interest expense | $53.1M | $99.3M | $81.3M | $80.4M | $46.8M | $36.7M | $8.8M | $2.5M | $13,000 |
| Income before taxes | −$735.0M | −$542.2M | −$653.3M | −$484.7M | −$586.5M | −$505.5M | −$288.6M | −$169.5M | −$43.8M |
| Income taxes | $555,000 | $1.2M | $71.5M | $9.3M | $52.8M | −$21.6M | −$28.1M | $16.8M | −$13.5M |
| Net income | −$729.3M | −$535.8M | −$643.2M | −$481.2M | −$562.5M | −$448.7M | −$260.4M | −$130.7M | −$30.6M |
| EBITDA | −$676.4M | −$436.8M | −$565.5M | −$397.4M | −$533.8M | −$467.4M | −$279.0M | −$183.4M | −$43.6M |
| EPS (diluted) | −$3.60 | −$3.36 | −$3.90 | −$3.75 | −$3.91 | −$3.80 | −$4.94 | −$1.42 | −$0.99 |
| Gross margin | 94.4% | 98.3% | 73.7% | 95.6% | 95.5% | 100.0% | 93.8% | — | — |
| Operating margin | −113.3% | −267.2% | −6,528.8% | −659.6% | −827.1% | −5,752.0% | −656.4% | — | — |
| Net margin | −145.3% | −241.4% | −6,913.9% | −619.7% | −806.9% | −5,439.7% | −642.1% | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $243.7M | $194.5M | $154.2M | $120.7M | $110.6M | $116.6M | $5.9M | $2.7M | $2.2M | $211.1M | $1.7M | $4.1M |
| Cost of revenue | $15.0M | $10.4M | $15.4M | $6.6M | $3.7M | $2.6M | $2.1M | $598,000 | $598,000 | $598,000 | $598,000 | $598,000 |
| Gross profit | $228.6M | $184.1M | $138.8M | $114.1M | $106.9M | $114.0M | $3.8M | $2.1M | $1.6M | $210.5M | $1.1M | $3.5M |
| Research & development | $149.4M | $126.6M | $142.0M | $112.9M | $111.2M | $111.4M | $130.3M | $120.4M | $114.7M | $141.0M | $130.2M | $125.1M |
| Sales, general & admin | $186.3M | $163.9M | $158.1M | $137.6M | $129.2M | $106.4M | $94.8M | $68.8M | $59.5M | $65.8M | $47.6M | $35.8M |
| Total operating expenses | $335.7M | $290.0M | $324.0M | $259.3M | $241.2M | $218.4M | $229.8M | $193.9M | $177.1M | $210.2M | $178.6M | $161.2M |
| Operating income | −$107.1M | −$106.0M | −$185.2M | −$145.2M | −$134.3M | −$104.4M | −$226.0M | −$191.8M | −$175.5M | $343,000 | −$177.4M | −$157.7M |
| Interest income | $6.7M | $6.2M | $4.3M | $6.2M | $3.9M | $5.4M | $4.7M | $3.3M | $5.2M | $4.1M | $5.6M | $3.8M |
| Interest expense | $13.3M | $52.8M | $12.0M | $11.7M | $37.6M | $42.1M | $29.8M | $23.1M | $22.9M | $23.5M | $20.3M | $20.3M |
| Income before taxes | −$155.9M | −$166.6M | −$197.2M | −$186.5M | −$181.7M | −$169.6M | −$266.2M | −$164.3M | −$75.5M | −$36.2M | −$170.3M | −$179.5M |
| Income taxes | −$6.2M | — | — | −$1.5M | $2.1M | $2.2M | $1.2M | — | −$2.1M | −$944,000 | $18.4M | −$1.6M |
| Net income | −$152.2M | −$164.0M | −$197.2M | −$182.7M | −$181.9M | −$167.4M | −$265.1M | −$162.0M | −$73.5M | −$35.2M | −$168.1M | −$177.0M |
| EBITDA | −$141.6M | −$112.6M | −$183.8M | −$173.3M | −$142.7M | −$126.2M | −$235.0M | −$139.7M | −$51.0M | −$11.1M | −$148.5M | −$157.5M |
| EPS (diluted) | −$0.78 | −$0.84 | −$0.94 | −$0.72 | −$0.95 | −$0.99 | −$1.37 | −$0.86 | −$1.01 | −$0.12 | −$0.96 | −$1.08 |
| Gross margin | 93.8% | 94.6% | 90.0% | 94.6% | 96.7% | 97.7% | 64.6% | 78.1% | 72.4% | 99.7% | 65.7% | 85.4% |
| Operating margin | −43.9% | −54.5% | −120.1% | −120.3% | −121.4% | −89.5% | −3,842.7% | −7,018.7% | −8,096.8% | 0.2% | −10,167.1% | −3,854.6% |
| Net margin | −62.5% | −84.3% | −127.9% | −151.4% | −164.5% | −143.5% | −4,506.1% | −5,931.2% | −3,388.2% | −16.7% | −9,636.0% | −4,326.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BBIO's financial statements (latest annual report filed February 24, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BBIO financial results
In fiscal year 2025 (ended December 31, 2025), BridgeBio Pharma reported revenue of $502.1 million, up 126.3% from the year before. It had a net loss of $729.3 million, a net profit margin of −145.3%. Diluted earnings per share came to −$3.60. Over five years revenue grew at an average rate of 127.4% a year.
See the BBIO stock overview for the latest quote and news, or the BBIO chart for price history and technical indicators.
BBIO income statement FAQ
What is BridgeBio Pharma's annual revenue?
BridgeBio Pharma reported total revenue of $502.1 million for fiscal year 2025, which ended on December 31, 2025. That was up 126.3% from $221.9 million the previous year.
Is BridgeBio Pharma profitable?
No. BridgeBio Pharma reported a net loss of $729.3 million in fiscal 2025, a net profit margin of −145.3%; its operating margin was −113.3%.
What is BridgeBio Pharma's gross margin?
BridgeBio Pharma's gross margin was 94.4% in fiscal 2025: for every $100 of revenue, BridgeBio Pharma kept $94 after the direct cost of its products and services.
How much does BridgeBio Pharma spend on research and development?
BridgeBio Pharma spent $477.5 million on research and development in fiscal 2025, 95.1% of revenue.
How fast is BridgeBio Pharma growing?
Revenue grew 127.4% a year on average over the last five fiscal years, from $8.2 million to $502.1 million.
What are BridgeBio Pharma's earnings per share?
BridgeBio Pharma earned $-3.60 per diluted share in fiscal 2025, compared with $-3.36 a year earlier.
When will BridgeBio Pharma report its next earnings?
BridgeBio Pharma is expected to report results for the quarter ending September 30, 2026 on November 4, 2026.
When does BridgeBio Pharma's fiscal year end?
BridgeBio Pharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 24, 2026.